Evaluation of silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
Gastroenterology and Hepatology from Bed to Bench,
Vol. 12 No. 2 (2019),
18 March 2019
,
Page 138-142
https://doi.org/10.22037/ghfbb.v12i2.1562
Abstract
Aim: This study was performed to evaluate the potential efficacy of silymarin in the management of anti-tuberculosis medication’s induced liver injury.
Background: Hepatic toxicity is the most serious complication in treatment of tuberculosis.
Methods: In a randomized double blind clinical trial (ACTRN12610000643077), 55 cases with hepatotoxicity caused by anti-tuberculosis drugs were divided into two groups. Informed consents were obtained. The intervention group received silymarin and the control group received placebo. Severity of liver injury, the duration necessary for normalization of liver function and hospital stay were compared between the two groups.
Results: There was not any statistically significant difference in the rate of adverse effects between silymarin and placebo groups.
Conclusion: Although silymarin is considered a safe herbal medication, it was not effective to treat hepatic toxicity of anti-tuberculosis drugs.
Keywords: Tuberculosis, Adverse effects, Silymarin, Drug induced hepatitis.
(Please cite as: Marjani M, Fahimi F, Sadr M, Kazempour Dizaji M, Moniri A, Shadi Khabiri6, et al. Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterol Hepatol Bed Bench 2019;12(2):138-142).
- Tuberculosis
- adverse effects
- Silymarin
- drug induced hepatitis
How to Cite
References
WHO. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. [Available from: http://www.who.int/tb/publications/global_report/en/]
Tostmann A, Boeree MJ, Aarnoutse RE, De Lange WC, Van Der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008;23:192-202.
Baghaei P, Tabarsi P, Chitsaz E, Saleh M, Marjani M, Shemirani S, et al. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am J Ther 2010;17:17-22.
Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026-30.
Kaona FA, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health 2004;4:68.
WHO. World Health Organization/IUATLD Global project on anti-tuberculous drug Resistance Surveillance. Anti-tuberculous Drug Resistance in the World. Third global report. WHO/HTM/TB/2004.343. Geneva: World Health Organization; 2004. [Available from: http://apps.who.int/iris/bitstream/10665/43103/1/9241562854.pdf]
Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006;124:491-504.
Vargas-Mendoza N, Madrigal-Santillan E, Morales-Gonzalez A, Esquivel-Soto J, Esquivel-Chirino C, Garcia-Luna YG-RM, et al. Hepatoprotective effect of silymarin. World J Hepatol 2014;6:144-9.
Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Exp Rev Gastroenterol Hepatol 2016;10:517-36.
Eminzade S, Uraz F, Izzettin FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab 2008;5:18.
WHO. World Health Organization: Treatment of tuberculosis: guidelines for national programmes. 3rd edition. Geneva: World Health Organization; 2010. [Available from: http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1]
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52.
Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85.
Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis 2007;87:551-6.
Jahan S, Khan M, Imran S, Sair M. The hepatoprotective role of Silymarin in isoniazid induced liver damage of rabbits. J Pak Med Assoc 2015;65:620-2.
Singh M, Sasi P, Gupta VH, Rai G, Amarapurkar DN, Wangikar PP. Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model. Hum Exp Toxicol 2012;31:788-97.
Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med 2015;15:334.
Gu J, Tang SJ, Tan SY, Wu Q, Zhang X, Liu CX, et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury. Int J Clin Exp Med 2015;8:4320-7.
Heo E, Kim DK, Oh SH, Lee JK, Park JH, Chung HS. Effect of Prophylactic Use of Silymarin on Anti-tuberculosis Drugs Induced Hepatotoxicity. Tuberc Respir Dis 2017;80:265-9.
Marjani M, Baghaei P, Kazempour Dizaji M, Gorji Bayani P, Fahimi F, Tabarsi P, et al. Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iran J Pharm Res 2016;15:247-52.
Zhang S, Pan H, Peng X, Lu H, Fan H, Zheng X, et al. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: a randomized controlled trial. J Gastroenterol Hepatol 2016;31:409-16.
- Abstract Viewed: 264 times
- PDF Downloaded: 117 times